Literature DB >> 24002642

RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer.

Jin Bai1, Hong-Mei Yong, Fei-Fei Chen, Wen-Bo Song, Chen Li, Hui Liu, Jun-Nian Zheng.   

Abstract

PURPOSE: To evaluate the role of RUNX3 in breast cancer pathogenesis, we examined the RUNX3 expression in breast cancer tissues and analyzed the correlation between RUNX3 expression and clinicopathologic variables and patients survival.
METHODS: We evaluated the RUNX3 expression by immunohistochemistry using a tissue microarray containing 256 specimens of breast cancer patients. We also studied the role of RUNX3 in cell migration and invasion by performing cell migration and invasion assay. Differential expression of metastasis-related genes after RUNX3 restoration was analyzed using the Human Tumor Metastasis PCR Array.
RESULTS: The RUNX3 expression was significantly correlated with breast cancer histology grade (P = 0.000), and low RUNX3 expression strongly correlated with worse 5-year overall and disease-specific survival rates (P = 0.000 and P = 0.001, respectively). Furthermore, we found that RUNX3 restoration suppressed breast cancer metastasis by controlling cell migration and invasion capacity. Finally, gene expression profiles of RUNX3-549 and Ctrl-549 cells showed matrix metalloproteinase-2 (MMP-2) was the most significant gene among the 84 metastasis-related genes influenced by RUNX3 reintroduction.
CONCLUSIONS: Reduced RUNX3 expression is significantly correlated with breast cancer progression and predicts worse survival. RUNX3 regulates breast cancer cell migration and invasion through the MMP-2 pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002642     DOI: 10.1007/s00432-013-1498-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.

Authors:  Wei Chen; Manuel Salto-Tellez; Nallasivam Palanisamy; Kumaresan Ganesan; Qingsong Hou; Lay Keng Tan; Lang Hiong Sii; Kosei Ito; Benita Tan; Jeanie Wu; Andrew Tay; Kok Chai Tan; Erik Ang; Bien Keem Tan; Puay Hoon Tan; Yoshiaki Ito; Patrick Tan
Journal:  Genes Chromosomes Cancer       Date:  2007-03       Impact factor: 5.006

Review 2.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

3.  ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.

Authors:  Jeanette Dupont Jensen; Ann Knoop; Marianne Ewertz; Anne-Vibeke Laenkholm
Journal:  Breast Cancer Res Treat       Date:  2011-06-11       Impact factor: 4.872

4.  RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration.

Authors:  Peng-Jin Mei; Jin Bai; Hui Liu; Chen Li; Yong-Ping Wu; Zheng-Quan Yu; Jun-Nian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-16       Impact factor: 4.553

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis.

Authors:  C Sakakura; K Miyagawa; K-I Fukuda; S Nakashima; T Yoshikawa; S Kin; Y Nakase; H Ida; S Yazumi; H Yamagishi; T Okanoue; T Chiba; K Ito; A Hagiwara; Y Ito
Journal:  Oncogene       Date:  2007-03-26       Impact factor: 9.867

Review 7.  Oncogenic transcription factors in the human acute leukemias.

Authors:  A T Look
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

8.  Sonographic appearance of invasive ductal carcinoma of the breast according to histologic grade.

Authors:  Jason Blaichman; James C Marcus; Tahra Alsaadi; Mona El-Khoury; Sarkis Meterissian; Benoít Mesurolle
Journal:  AJR Am J Roentgenol       Date:  2012-09       Impact factor: 3.959

Review 9.  Molecular pathology of RUNX3 in human carcinogenesis.

Authors:  Manish Mani Subramaniam; Jason Yongsheng Chan; Khay Guan Yeoh; Timothy Quek; Kosei Ito; Manuel Salto-Tellez
Journal:  Biochim Biophys Acta       Date:  2009-08-12

10.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

View more
  5 in total

1.  Cullin1 is up-regulated and associated with poor patients' survival in hepatocellular carcinoma.

Authors:  Wen Liu; You Wang; Chuanling Zhang; Baoshan Huang; Jin Bai; Lijun Tian
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

2.  Complement C1q binding protein regulates T cells' mitochondrial fitness to affect their survival, proliferation, and anti-tumor immune function.

Authors:  Hui Tian; Gang Wang; Qiping Wang; Baofu Zhang; Guan Jiang; Huizhong Li; Dafei Chai; Lin Fang; Meng Wang; Junnian Zheng
Journal:  Cancer Sci       Date:  2022-01-20       Impact factor: 6.716

3.  The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis.

Authors:  Xiao-Yun Song; Bo-Yan Li; En-Xiang Zhou; Feng-Xia Wu
Journal:  Onco Targets Ther       Date:  2016-08-26       Impact factor: 4.147

Review 4.  An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.

Authors:  De-Guo Lu; Ying-Mei Ma; Ai-Ju Zhu; Yun-Wei Han
Journal:  Oncotarget       Date:  2017-03-28

5.  Inactivation of RUNX3 protein expression in tongue squamous cell carcinoma and its association with clinicopathological characteristics.

Authors:  Wei-Na Zhou; Yi-Fei Du; Yang Zheng; Wei Zhang; Yu-Nong Wu; Xiao-Meng Song; Jin Bai
Journal:  Mol Med Rep       Date:  2018-11-29       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.